Compare PRE & YI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRE | YI |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | Hong Kong | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Retail-Drug Stores and Proprietary Stores |
| Sector | Industrials | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.3M | 38.1M |
| IPO Year | N/A | N/A |
| Metric | PRE | YI |
|---|---|---|
| Price | $14.96 | $3.60 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $32.00 | N/A |
| AVG Volume (30 Days) | ★ 137.5K | 12.2K |
| Earning Date | 11-10-2025 | 12-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $77,079,000.00 | ★ $1,979,883,442.00 |
| Revenue This Year | $219.28 | N/A |
| Revenue Next Year | $124.38 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 201.54 | N/A |
| 52 Week Low | $3.10 | $3.19 |
| 52 Week High | $17.99 | $11.35 |
| Indicator | PRE | YI |
|---|---|---|
| Relative Strength Index (RSI) | 54.79 | 40.53 |
| Support Level | $12.93 | $3.32 |
| Resistance Level | $15.70 | $3.94 |
| Average True Range (ATR) | 1.14 | 0.23 |
| MACD | 0.10 | 0.03 |
| Stochastic Oscillator | 67.33 | 51.22 |
Prenetics Global Ltd is a health sciences company dedicated to consumer and clinical health. Its consumer initiative is led by IM8, a new health and wellness brand, and Europa, a U.S. sports distribution company. The clinical division is led by Insighta, focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer DNA tests. Each Prenetics unit impacts health by 'enhancing life through science'.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.